TrippBio, with a valuation of $24.82 million, is raising funds on StartEngine. The company is discovering, developing, and commercializing innovative antiviral treatments. TrippBio’s anticipated flagship drug, PanCytoVir, aims to target viral pathogens with high efficiency and low risk, and has completed Phase 2 clinical trials. The company is led by an experienced team and is focused on discovering the treatment for emerging respiratory diseases. William Meadow and Dr. David E. Martin founded TrippBio in May 2020. The current crowdfunding campaign has a minimum target of $14,999.88 and a maximum target of $617,999.76. The campaign proceeds will be used for research and development, marketing, company employment, and intellectual property development.
Investment Overview
Raised: $5,554
Deal Terms
Total Commitments ($USD)
- Platform
- StartEngine
- Start Date
- 11/14/2024
- Close Date
- 02/11/2025
$15,000
$618,000
$250
Equity - Common
Seed
RegCF
$0.42
$24,820,583
Company & Team
Company
- Year Founded
- 2020
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B2C
- Margin
- Medium
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $1,395,744
- VC Backed?
- No
Growth Charts
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Valuation History
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.